Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy.
Li JY, Perry SR, Muniz-Medina V, Wang X, Wetzel LK, Rebelatto MC, Hinrichs MJ, Bezabeh BZ, Fleming RL, Dimasi N, Feng H, Toader D, Yuan AQ, Xu L, Lin J, Gao C, Wu H, Dixit R, Osbourn JK, Coats SR. Li JY, et al. Among authors: osbourn jk. Cancer Cell. 2016 Jan 11;29(1):117-29. doi: 10.1016/j.ccell.2015.12.008. Cancer Cell. 2016. PMID: 26766593 Free article.
A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy.
Li JY, Perry SR, Muniz-Medina V, Wang X, Wetzel LK, Rebelatto MC, Masson Hinrichs MJ, Bezabeh BZ, Fleming RL, Dimasi N, Feng H, Toader D, Yuan AQ, Xu L, Lin J, Gao C, Wu H, Dixit R, Osbourn JK, Coats SR. Li JY, et al. Among authors: osbourn jk. Cancer Cell. 2019 Jun 10;35(6):948-949. doi: 10.1016/j.ccell.2019.05.010. Cancer Cell. 2019. PMID: 31185215 Free article. No abstract available.
Preclinical Characterization of an Antibody-Drug Conjugate Targeting CS-1 and the Identification of Uncharacterized Populations of CS-1-Positive Cells.
Chen R, Rajan S, Overstreet MG, Hurt EM, Thomas SB, Muniz-Medina V, Ward C, Sadowska A, Fleming R, Karanth S, Breen S, Zheng B, Wu Y, Iverson WO, Novick S, O'Day T, Shah DP, Dimasi N, Tiberghien AC, Osbourn J, Walker J. Chen R, et al. Mol Cancer Ther. 2020 Aug;19(8):1649-1659. doi: 10.1158/1535-7163.MCT-19-0482. Epub 2020 May 13. Mol Cancer Ther. 2020. PMID: 32404408
A Therapeutic Uricase with Reduced Immunogenicity Risk and Improved Development Properties.
Nyborg AC, Ward C, Zacco A, Chacko B, Grinberg L, Geoghegan JC, Bean R, Wendeler M, Bartnik F, O'Connor E, Gruia F, Iyer V, Feng H, Roy V, Berge M, Miner JN, Wilson DM, Zhou D, Nicholson S, Wilker C, Wu CY, Wilson S, Jermutus L, Wu H, Owen DA, Osbourn J, Coats S, Baca M. Nyborg AC, et al. PLoS One. 2016 Dec 21;11(12):e0167935. doi: 10.1371/journal.pone.0167935. eCollection 2016. PLoS One. 2016. PMID: 28002433 Free PMC article.
Human Relaxin-2 Fusion Protein Treatment Prevents and Reverses Isoproterenol-Induced Hypertrophy and Fibrosis in Mouse Heart.
Sun J, Hao W, Fillmore N, Ma H, Springer D, Yu ZX, Sadowska A, Garcia A, Chen R, Muniz-Medina V, Rosenthal K, Lin J, Kuruvilla D, Osbourn J, Karathanasis SK, Walker J, Murphy E. Sun J, et al. J Am Heart Assoc. 2019 Dec 17;8(24):e013465. doi: 10.1161/JAHA.119.013465. Epub 2019 Dec 10. J Am Heart Assoc. 2019. PMID: 31818212 Free PMC article.
Engineering of a GLP-1 analogue peptide/anti-PCSK9 antibody fusion for type 2 diabetes treatment.
Chodorge M, Celeste AJ, Grimsby J, Konkar A, Davidsson P, Fairman D, Jenkinson L, Naylor J, White N, Seaman JC, Dickson K, Kemp B, Spooner J, Rossy E, Hornigold DC, Trevaskis JL, Bond NJ, London TB, Buchanan A, Vaughan T, Rondinone CM, Osbourn JK. Chodorge M, et al. Among authors: osbourn jk. Sci Rep. 2018 Dec 3;8(1):17545. doi: 10.1038/s41598-018-35869-4. Sci Rep. 2018. PMID: 30510163 Free PMC article.
27 results